Compensation between Vav-1 and Vav-2 in B cell development and antigen receptor signaling

Nature Immunology

Volumn 2, Issue 6, 2001, Pages 548-555

  Tedford, Kerry ^a,b   Nitschke, Lars ^b   Girkontaite, Irute ^a   Charlesworth, Amanda ^c   Chan, Gordon ^a,b   Sakk, Vadim ^a   Barbacid, Mariano ^d   Fischer, Klaus Dieter ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF CHICAGO   (United States)

^d M Barbacid Ctro Nac Invest O   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; ONCOPROTEIN; PRIMER DNA; VAV PROTEIN; VAV1 PROTEIN, MOUSE; VAV2 PROTEIN, MOUSE;

ANIMAL; ARTICLE; B LYMPHOCYTE; CALCIUM SIGNALING; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; MOUSE MUTANT; NUCLEOTIDE SEQUENCE;

ANIMALS; B-LYMPHOCYTES; BASE SEQUENCE; CALCIUM SIGNALING; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; DNA PRIMERS; MICE; MICE, KNOCKOUT; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-VAV; RECEPTORS, ANTIGEN, B-CELL;

EID: 0035374589     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/88756     Document Type: Article

References (57)

1. Benschop, R. J. & Cambier, J. C. B cell development signal transduction by antigen receptors and their surrogates. Curr. Opin. Immunol. 11, 143-151 (1999).
2. Pillai, S. The chosen few? Positive selection and the generation of naive B lymphocytes. Immunity 10, 493-502 (1999).
3. Carsetti, R., Kohler, G. & Lamers, M. C. Transitional B cells are the target of negative selection in the B cell compartment. J. Exp. Med. 181, 2129-2140 (1995).
4. Melamed, D., Benscnop, R. J., Cambier, J. C. & Nemazee, D. Developmental regulation of B lymphocyte immune tolerance comparmentalizes clonal selection from receptor selection. Cell 92, 173-182 (1998).
5. Kurosaki, T. Functional dissection of BCR signaling pathways. Curr. Opin. Immunol 12, 276-281 (2000).
6. Kerner, J. D. et al. Impaired expansion of mouse B cell progenitors lacking Btk. Immunity 3, 301-312 (1995).
7. Khan, W. N. et al. Defective B cell development and function in Btk-deficient mice. Immunity 3, 283-299 (1995).
8. Fruman, D. A. et al. Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85α. Science 283, 393-397 (1999).
9. Suzuki, H. et al. Xid-like immunodeficiency in mice with disruption of the p85α subunit of phosphoinositide 3-kinase. Science 283, 390-392 (1999).
10. Jumaa, H. et al. Abnormal development and function of B lymphocytes in mice deficient for the signaling adaptor protein SLP-65. Immunity 11, 547-554 (1999).
11. Pappu, R. et al. Requirement for B cell linker protein (BLNK) in B cell development. Science 286, 1949-1954 (1999).
12. Hayashi, K. et al. The B cell-restricted adaptor BASH is required for normal development and antigen receptor-mediated activation of B cells. Proc. Natl Acad. Sci. USA 97, 2755-2760 (2000).
13. Xu, S. et al. B cell development and activation defects resulting in xid-like immunodeficiency in BLNK/SLP-6S-deficient mice. Int. Immunol. 12, 397-404 (2000).
14. Wang, D. et al. Phospholipase Cγ2 is essential in the functions of B cell and several Fc receptors. Immunity 13, 25-35 (2000).
15. Fruman, D. A., Satterthwaite, A. B. & Witte, O. N. Xid-like phenotypes: a B cell signalosome takes shape. Immunity 13, 1-3 (2000).
16. Bishop, A. L. & Hall, A. Rho GTPases and their effector proteins. Biochem. J. 348, 241-255 (2000).
17. Bustelo, X. R. Regulatory and signaling properties of the Vav family. Mol Cell Biol. 20, 1461-1477 (2000).
18. Bustelo, X. R., Rubin, S. D., Suen, K. L., Carrasco, D. & Barbacid, M. Developmental expression of the vav protooncogene. Cell. Growth Differ. 4, 297-308 (1993).
19. Schuebel, K. E. et al. Isolation and characterization of murine vav-2, a member of the vav family of proto-oncogenes. Oncogene 13, 363-371 (1996).
20. Movilla, N. & Bustelo, X. R. Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol. Cell Biol. 19, 7870-7885 (1999).
21. Fischer, K. D., Tedford, K. & Penninger, J. M. Vav links antigen-receptor signaling to the actin cytoskeleton. Semin. Immunol. 10, 317-327 (1998).
22. + thymocytes. Nature 374, 474-7 (1995).
23. Turner, M. et al. A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes. Immunity 7, 451-460 (1997).
24. Kong, Y.Y. et al. Vav regulates peptide-specific apoptosis in thymocytes. J. Exp. Med. 188, 2099-2111 (1998).
25. Krawczyk, C. et al. Cbl-b is a negative regulator of receptor clustering and raft aggregation in T cells. Immunity 13, 463-473 (2000).
26. Zhang, R., Alt, F. W., Davidson, L., Orkin, S. H. & Swat, W. Defective signalling through the T- and B-cell antigen receptors in lymphoid cells lacking the vav proto-oncogene. Nature 374, 470-473 (1995).
27. Fischer, K. D. et al. Vav is a regulator of cytoskeletal reorganization mediated by the T- cell receptor. Curr. Biol. 8, 554-562 (1998).
28. Tarakhovsky, A. et al. Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav. Nature 374, 467-470 (1995).
29. Holsinger, L. J. et al. Defects in actin-cap formation in Vav-deficient mice implicate an actin requirement for lymphocyte signal transduction. Curr. Biol. 8, 563-572 (1998).
30. O'Rourke, L. M. et al. CD19 as a membrane-anchored adaptor protein of B lymphocytes: costimulation of lipid and protein kinases by recruitment of Vav. Immunity 8, 635-645 (1998).
31. Bachmann, M. F. et al. The guanine-nucleotide exchange factor Vav is a crucial regulator of B cell receptor activation and B cell responses to nonrepetitive antigens. J. Immunol. 163, 137-142 (1999).
32. Gulbranson-Judge, A. et al. Defective immunoglobulin class switching in Vav-deficient mice is attributable to compromised T cell help. Eur. J. Immunol. 29, 477-487 (1999).
33. Loder, F. et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of the B cell receptor-derived signals. J. Exp. Med. 190, 75-89 (1999).
34. Klaus, G. G., Holman, M., Johnson-Leger, C., Elgueta-Karstegl, C. & Atkins, C. A re-evaluation of the effects of X-linked immunodeficiency (xid) mutation on B cell differentiation and function in the mouse. Eur. J. Immunol. 27, 2749-2756 (1997).
35. Doody, G. M. et al. Vav-2 controls NFAT-dependent transcription in B- but not T-lymphocytes. EMBO J. 19, 6173-4184 (2000).
36. Moores, S. L. et al. Vav family proteins couple to diverse cell surface receptors. Mol. Cell Biol. 20, 6364-7633 (2000).
37. Deckert, M., Tartare-Deckert, S., Couture, C., Mustelin, T. & Altman, A. Functional and physical interactions of Syk family kinases with the Vav proto-oncogene product. Immunity 5, 591-604 (1996).
38. Wu, J., Zhao, Q., Kurosaki, T. & Weiss, A. The Vav binding site (Y315) in ZAP-70 is critical for antigen receptor- mediated signal transduction. J. Exp. Med. 185, 1877-1882 (1997).
39. Fu, C., Turck, C. W., Kurosaki, T. & Chan, A. C. BLNK: a central linker protein in B cell activation. Immunity 9, 93-103 (1998).
40. Wienands, J. et al. SLP-65: a new signaling component in B lymphocytes which requires expression of the antigen receptor for phosphorylation. J. Exp. Med. 188, 791-795 (1998).
41. Kelly, M. E. & Chan, A. C. Regulation of B cell function by linker proteins. Curr. Opin. Immunol. 12, 267-275 (2000).
42. Han, J. et al. Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science 279, 558-560 (1998).
43. Fu, C. & Chan, A. C. Identification of two tyrosine phosphoproteins, pp70 and pp68, which interact with phospholipase Cγ, Grb2, and Vav after B cell antigen receptor activation. J. Biol. Chem. 272, 27362-27368 (1997).
44. Hashimoto, S. et al. Identification of the SH2 domain binding protein of Bruton's tyrosine kinase as BLNK - functional significance of Btk-SH2 domain in B-cell antigen receptor-coupled calcium signaling. Blood 94, 2357-2364 (1999).
45. Su, Y. W. et al. Interaction of SLP adaptors with the SH2 domain of Tec family kinases. Eur J. Immunol. 29, 3702-3711 (1999).
46. Aman, M. J. & Ravichandran, K. S. A requirement for lipid rafts in B cell receptor induced Ca(2+) flux. Curr. Biol. 10, 393-396 (2000).
47. Guo, B., Kato, R. M., Garcia-Lloret, M., Wahl, M. I. & Rawlings, D. J. Engagement of the human pre-B cell receptor generates a lipid raft-dependent calcium signaling complex. Immunity 13, 243-253 (2000).
48. Weng, W. K., Jarvis, L. & LeBien, T. W. Signaling through CD19 activates Vav/mitogen-activated protein kinase pathway and induces formation of a CD19/Vav/phosphatidylinositol 3-kinase complex in human B cell precursors. J. Biol. Chem. 269, 32514-32521 (1994).
49. Tedder, T. F., Inaoki, M. & Sato, S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 6, 107-118 (1997).
50. Crespo, P., Schuebel, K. E., Ostrom, A. A., Gutkind, J. S. & Bustelo, X. R. Phosphotyrosine-dependent activation of Rac-I GDP/GTP exchange by the vav proto-oncogene product. Nature 385, 169-172 (1997).
51. Schuebel, K. E., Movilla, N., Rosa, J. L. & Bustelo, X. R. Phosphorylation-dependent and constitutive activation of Rho proteins by wild-type and oncogenic Vav-2. EMBO J. 17, 6608-6621 (1998).
52. Tybulewicz, V. L., Crawford, C. E., Jackson, P. K., Bronson, R. T. & Mulligan, R. C. Neonatal lethality and lymphopenia in mice with a homorygous disruption of the c-abl proto-oncogene. Cell 65, 1153-1163 (1991).
53. Ogilvy, S. et al. Transcriptional regulation of Vav, a gene expressed throughout the hematopoietic compartment. Blood 91, 419-430 (1998).
54. Zmuidzinas, A. et al. The Vav proto-oncogene is required early in embryogenesis but not for hematopoietic development in vitro. EMBO J. 14, 1-11 (1995).
55. Rolink, A., Kudo, A., Karasuyama, H., Kikuchi, Y. & Melchers, F. Long-term proliferating early pre B cell lines and clones with the potential to develop to surface Ig-positive, mitogen reactive B cells in vitro and in vivo. EMBO J. 10, 327-336 (1991).
56. Fong, G. H., Rossant, J., Gertsenstein, M. & Breitman, M. L. Role of the Flt-I receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376, 66-70 (1995).
57. Rolink, A., Melchers, F. & Andersson, J. The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity 5, 319-330 (1996).